Anvarxodjaeva Sh.G. (1), Eshmurzaeva A.A. (2)
The aim of this study was to evaluate the diagnostic and prognostic significance of anti-mutated citrullinated vimentin (anti-MCV) antibodies, anti-keratin antibodies (AKA), and interleukin-6 (IL-6) in patients with rheumatoid arthritis (RA) undergoing methotrexate-based therapy. A 12-month prospective observational study was conducted involving 76 patients with both early and established RA. A comprehensive assessment was performed, including clinical disease activity evaluation, serum levels of anti-MCV, AKA, rheumatoid factor (RF), and IL-6, as well as dynamic radiographic monitoring. Elevated levels of anti-MCV and IL-6 were found to be associated with high inflammatory activity and rapid progression of joint erosions. Notably, anti-MCV showed particular diagnostic value in patients with seronegative RA. A reduction in anti-MCV and IL-6 levels correlated with the achievement of clinical remission during therapy. The novelty of this study lies in demonstrating the prognostic value of anti-MCV and IL-6 as biomarkers for monitoring the long-term effectiveness of RA treatment.
1. Ubshaeva YuB. Clinical features and management of rheumatoid arthritis with high levels of pro-inflammatory cytokines. Rheumatology Research. 2015.
2. Oransky SP, Eliseeva LN. Dynamics of serum cytokine and endothelial biomarkers in rheumatoid arthritis during course therapy. Fundamental Research. 2012;(12):112–6. Available from: https://s.fundamental-research.ru/pdf/2012/2012121.pdf#page=112
3. Avdeeva AS, Novikov AA, Ponomareva OV. Correlation between cytokine levels, disease activity, autoantibody levels, and destructive joint changes in early rheumatoid arthritis. Scientific and Practical Rheumatology. 2015;53(2):45–52. https://doi.org/10.14412/1995-4484-2015-488
4. Gavrilă BI, Ciofu C, Stoica V. Biomarkers in rheumatoid arthritis, what is new? J Med Life. 2016;9(2):144–8. Available from: https://pdfs.semanticscholar.org/2811/d69125f3cedf12b0180add0ab79f35f23bd4.pdf
5. López-Romero P, Martinez-Gamboa L, Bang H. Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with methotrexate. Arthritis Res Ther. 2020;22:284. https://doi.org/10.1186/s13075-020-02284-y
6. Ali DA, Al-Anee MM, Al-Anee NA. Assessment of the correlation between disease activity and serum biomarker Anti-MCV and IL6 in Iraqi patients with rheumatoid arthritis. J Fac Med Baghdad. 2024;66(1):41–8. Available from: https://www.iasj.net/iasj/download/5de6ef6e4bd9f7af
7. Zhu JN, Nie MJ, Li C, Deng YS, Zheng WX. Diagnostic value of anti-MCV antibodies in rheumatoid arthritis: A systematic review and meta-analysis. Clin Chem Lab Med. 2019;57(9):1289–98. https://doi.org/10.1515/cclm-2019-0167
8. Hassoon HJ, Abbas AAH, Jasim WE. Diagnostic value of anti-MCV antibodies in rheumatoid arthritis patients in Iraq. Iraqi J Sci. 2020;61(11):2850–7. Available from: https://www.iasj.net/iasj/download/8c6d28004a73a586
9. Ali OSM, Khalifa AIM, El-Shaer SSM. Study of the diagnostic value of anti-MCV and MMP3 biomarkers in serum and synovial fluid of rheumatoid arthritis patients. Int J Pharm Appl Sci. 2015;7(1):1–7. Available from: https://www.researchgate.net/publication/316066215
10. Reyes-Pérez IV, Sánchez-Hernández PE, Flores-Chávez A, et al. Serum cytokine profiles and their relationship with antibodies to citrullinated proteins in rheumatoid arthritis. Clin Rheumatol. 2019;38(12):3473–82. https://doi.org/10.1007/s10067-019-04681-4
11. Zahran WE, Mahmoud MI, Shalaby KA. Anti-mutated citrullinated vimentin antibodies in rheumatoid arthritis: Diagnostic and prognostic significance. Egypt Rheumatol Rehabil. 2013;40(1):27–35. https://doi.org/10.4103/1110-161X.123796
12. Voronina MS, Vinogradov AA. Diagnostic markers and cytokine profile in rheumatoid arthritis against the background of basic therapy. Scientific and Practical Rheumatology. 2012;50(1):50–5. Available from: https://cyberleninka.ru/article/n/diagnosticheskie-markery-i-tsitokinovyy-profil-pri-revmatoidnom-artrite-na-fone-bazisnoy-terapii
13. López-Hoyos M, Calvo-Alén J. New autoantibodies in rheumatoid arthritis: Significance and clinical utility. Curr Opin Rheumatol. 2019;31(3):231–6. https://doi.org/10.1097/BOR.0000000000000583
14. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38. https://doi.org/10.1016/S0140-6736(16)30173-8